Aztreonam/avibactam
Combination antibiotic medication / From Wikipedia, the free encyclopedia
Aztreonam/avibactam, sold under the brand name Emblaveo, is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections.[1][2][3][4] Drug resistance to the combination has been reported.[5]
Quick Facts Combination of, Avibactam ...
Combination of | |
---|---|
Aztreonam | β-lactam antibiotic |
Avibactam | β-Lactamase inhibitor |
Clinical data | |
Trade names | Emblaveo |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
KEGG |
Close
The combination was approved for medical use in the European Union in April 2024.[1][6]